Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...
and 25% to 30% of them develop nasal polyps as a result. Sanofi and Regeneron have said that CRSwNP has been helping to drive increased sales of Dupixent, which is approved for a range of ...
Zacks.com on MSN4mon
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary GoalsBesides Dupixent, Nucala faces strong competition ... AZN is also evaluating Fasenra in late-stage studies for treating nasal ...
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...
Get Instant Summarized Text (Gist) Asthma and antibiotic use at the time of initial endoscopic sinus surgery increase the likelihood of nasal polyp recurrence, necessitating revision surgery. Age ...
chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, among others. The growth runway has not yet run its course. In September 2024, DUPIXENT was approved by the FDA for treatment of ...
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
The SWIFT studies achieved their co-primary endpoints – treatment with depemokimab led to a statistically significant reduction in nasal polyp size ... the FDA expanded Dupixent’s label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback